588702-69-6 Usage
Uses
Used in Pharmaceutical Industry:
Methyl 3-trifluoro-2-pyridinecarboxylate is used as an intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs and improving the efficacy of existing ones. Its high reactivity allows for the creation of a wide range of chemical compounds, making it a valuable asset in the pharmaceutical field.
Used in Agrochemical Industry:
In the agrochemical industry, methyl 3-trifluoro-2-pyridinecarboxylate is utilized as an intermediate in the production of various agrochemicals, such as pesticides and herbicides. Its reactivity and versatility enable the synthesis of effective and targeted agrochemicals, helping to protect crops and enhance agricultural productivity.
Used in Organic Synthesis:
Methyl 3-trifluoro-2-pyridinecarboxylate serves as a building block in organic synthesis, allowing for the creation of a diverse array of chemical compounds. Its unique structure and reactivity make it an essential component in the synthesis of complex organic molecules, further expanding its applications in various industries.
Used in Chemical Reactions as a Reagent:
As a reagent in chemical reactions, methyl 3-trifluoro-2-pyridinecarboxylate is employed to facilitate various chemical processes and transformations. Its high reactivity and ability to participate in a wide range of reactions make it a valuable tool in the synthesis of fine chemicals and other specialty chemicals.
Check Digit Verification of cas no
The CAS Registry Mumber 588702-69-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,8,8,7,0 and 2 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 588702-69:
(8*5)+(7*8)+(6*8)+(5*7)+(4*0)+(3*2)+(2*6)+(1*9)=206
206 % 10 = 6
So 588702-69-6 is a valid CAS Registry Number.
588702-69-6Relevant academic research and scientific papers
IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17
-
Page/Page column 209, (2021/11/06)
The present application discloses compounds having the following formula: (I), or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.
